ENVB

Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for the treatment of mental health disorders. The company's research focuses on next-generation synthetic cannabinoid derivatives designed to avoid psychoactive effects while retaining therapeutic benefits. Enveric is advancing candidates for conditions including anxiety, depression, and other psychiatric disorders. The company utilizes computational drug design and preclinical testing to develop proprietary compounds with improved safety and efficacy profiles.